Escalon Medical 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Escalon Medical 's ROA in the third quarter of 2026?
Escalon Medical Corp achieved a return on average assets (ROA) of 29.61 % in its third quarter of 2026, this is above ESMC's average return on assets of -6.83%.
Escalon Medical Corp assets over the 12 months ending in its third quarter of 2026 are valued at $5 million

ROA has improved compared to 4.91% in the second quarter of 2025, due to net income growth.

However, within the Healthcare sector 34 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Mar 31 2026 quarter, so far to 2725, from total ROA ranking in the second quarter of 2025 at 3268.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Mar 31 2026) III. Quarter	(Dec 31 2025) II. Quarter	(Sep 30 2025) I. Quarter	(Jun 30 2025) IV. Quarter	(Mar 31 2025) III. Quarter
Y / Y Total Assets Change	-6.15 %	44.43 %	58.01 %	-0.36 %	58.01 %
Y / Y Net Income Change	-	-	-	329.37 %	-
Net Income (TTM) in million	2	0	0	0	0
Return On Assets (TTM)	29.61 %	4.91 %	2.12 %	8.97 %	-0.89 %
ESMC's Total Ranking	# 2725	# 3268	# 2777	# 2955	# 2888
Total Assets (TTM) in million	5	8	5	5	5
Seq. Total Assets Change	-37.79 %	50.85 %	8.98 %	-8.24 %	-4.26 %
Seq. Net Income Change	2046.3 %	-	-	-	-

ESMC's 5 Years Annual ROA >> Back to ESMC Management Effectiveness >> Compare ESMC ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 9
Sector	# 35
Overall	# 138

Return On Assets Statistics
High	Average	Low
29.2 %	-6.83 %	-63.4 %
(Mar 31 2026)		(Dec 31 2013)

Financial Statements
Escalon Medical 's Assets	$ 5 million	ESMC's Balance sheet
Escalon Medical 's Income	$ 1 million	Quarterly ESMC's Income Statement
ESMC's Income by Division		See ESMC's Income by Division

Annual Return On Assets	(Jun 30 2025) FY 2025	(Jun 30 2024) FY 2024	(Jun 30 2023) FY 2023	(Jun 30 2022) FY 2022	(Jun 30 2021) FY 2021
Y / Y Total Assets Change	38.67 %	-18.95 %	10.26 %	-17.65 %	-6.98 %
Total Assets in million	4	3	4	4	4
Y / Y Net Income Change	-	-	1408.84 %	-	-
Net Income in million	0	0	0	0	0
Annual Return On Assets	1.82 %	-3.97 %	7 %	0.51 %	-1.21 %

ESMC's 5 Years Annual ROA >> Back to ESMC Management Effectiveness >> Compare ESMC ROA to its Competitors

Comment on ESMC's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 1.82 % compared to prior year, due to annual net income growth of % to $0.08 million, while value of Escalon Medical 's overall assets grew just by 38.67 % to $4.38 million, compared to $4.38 a year before.

More Return On Assets Ratios
ESMC's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ESMC's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ESMC's Competitors
Subscribers only: Roa for Escalon Medical 's Suppliers
Subscribers only: Return On Assets for ESMC's Customers

You may also want to know
ESMC's Roi	ESMC's Inventory Turnover Ratio	ESMC's Growth Rates	ESMC's Dividend Comparisons
	ESMC's Profitability Ratios	ESMC's Asset Turnover Ratio	ESMC's Dividend Growth
ESMC's Roe	ESMC's Valuation Ratios	ESMC's Financial Strength Ratios	ESMC's Dividend Payout Ratio

Companies with similar Return On Assets at Mar 31 2026, within Healthcare Sector	ROA
Sanuwave Health Inc	74.94 %
Entera Bio Ltd	74.79 %
Pulmatrix Inc	70.49 %
Exelixis Inc	67.15 %
Petros Pharmaceuticals inc	67.03 %
Advanced Biomed Inc.	60.23 %
Fortress Biotech Inc	58.36 %
Q32 Bio Inc	53.33 %
Coherus Oncology inc	50.33 %
Oramed Pharmaceuticals Inc	49.88 %
Aurinia Pharmaceuticals Inc	47.61 %
Zevra Therapeutics Inc	45.60 %
Earth Science Tech Inc	44.55 %
Tg Therapeutics Inc	42.77 %
Lensar Inc	42.26 %
Elite Pharmaceuticals Inc	38.74 %
Dariohealth Corp	37.08 %
Omeros Corporation	34.53 %
Idexx Laboratories Inc	32.56 %
Innoviva Inc	32.36 %
Agenus Inc	30.03 %
Abeona Therapeutics Inc	29.55 %
Escalon Medical Corp	29.20 %
Protagenic Therapeutics Inc new	27.96 %
Adma Biologics Inc	27.37 %
Rafael Holdings Inc	26.85 %
Acadia Pharmaceuticals Inc	26.24 %
Ironwood Pharmaceuticals inc	26.02 %
Theravance Biopharma inc	25.46 %
Spero Therapeutics Inc	24.95 %

Date modified: 2026-09-12T06:11:25+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.